← Back to headlines
Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition
Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.
17 Feb, 18:07 — 17 Feb, 18:07
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
PNP probes ₱16.12-M smuggled cigarettes in Lanao del Sur trucks
just now
Former Speaker Romualdez Faces Corruption Probe, Travel Ban
just now
Philippine Government Urges Agencies to Expedite Food Transport Amid High Fuel Prices
just now